Royalty Pharma revenue and financials
$56.44Change from previous close: −0.39%Absolute change: −$0.22
In the fiscal year ended December 2025, Royalty Pharma reported revenue of $2.38B (+5.06% year over year). Net income was $770.95M, a net margin of 32.4%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +5.06%
- 2025 vs 2024
- Net income growth
- −10.25%
- 2025 vs 2024
- Net margin
- 32.4%
- 2024: 37.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 728 | 718 | 827 | 703 | 364 | 596 | 743 | 704 | 658 | 665 | 773 | 574 |
| Depreciation and amortization | 1.3 | 1.2 | 1.2 | 1.3 | 1.4 | — | — | — | — | — | — | — |
| Investing cash flow | -230 | -478 | -848 | -958 | -312 | 504 | -506 | -1,193 | -893 | -86.7 | -1,000 | -451 |
| Financing cash flow | -273 | -273 | -300 | 563 | -508 | -941 | -258 | -326 | 1,157 | -212 | -232 | -1,359 |
| Dividends paid | -105 | -104 | -94.3 | -95.3 | -93.2 | -95.4 | -93.7 | -94.1 | -94.9 | -93.8 | -89.3 | -89.8 |
| Share repurchases | -44.6 | -50.1 | -80.5 | -146 | -292 | -709 | -52.6 | -97.0 | -80.0 | — | -30.2 | -140 |
| Debt issued | — | — | 0.0 | 3,229 | — | — | — | — | 1,471 | — | 350 | — |
| Debt repaid | — | — | 0.0 | -2,275 | — | — | — | — | — | — | -350 | -1,000 |
| Net change in cash | 226 | -32.3 | -320 | 307 | -456 | 159 | -21.0 | -815 | 922 | 366 | -459 | -1,237 |
| Free cash flow | 728 | 718 | 827 | 703 | 364 | — | — | — | — | — | — | — |
| Levered free cash flow | -122 | -12.0 | -325 | -737 | 84.9 | 298 | -240 | -895 | -523 | -101 | -602 | -437 |